SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Fountain Pharmaceuticals (FPHI)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark Fisner who wrote (22)8/13/1997 1:08:00 AM
From: r. peter Dale   of 78
 
Mark-

With all the carnage in the biotechs today, FPHI remains up 25% for the week. You're right about the contest: your choice of FPHI was by far the best (and if it had remained near its high on Monday of 0.40, the increase would have been ~150%). #1 out of probably hundreds of entries - in a down market - not too shabby my man. You probably know this but that Wyoming group has very deep pockets and, when they pledge their support, financing for the targeted company (i.e. Fountain) is no longer a problem...long term. My impression is that you ain't seen nothin' yet with this stock.

In your interferon-gamma treatments are you finding nitrosylated intermediates other than n-tyr? Can you actually isolate the oligos that are buying the farm or do you just see the LFB fall off? Also any more info on Zn/Cu SOD - is it regulated by the treatment ? Get on with those backcrosses man-you may have a Nature paper awaiting you. The demyelination field is so stuck up with EAE dogmatists that your model will leave them slappy. BTW, try using the Boeringer Mannheim FITC-dUTP instead of the entire Promega kit for your TUNELs - much more cost effective. Was great to see you in Mystic.

Best wishes,
Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext